Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind placebo-controlled study of TQB3702 in systemic lupus erythematosus
CTR20244964Phase 2Completed
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of TQB3702 in systemic lupus erythematosus (SLE), sponsored by Chia Tai-Tianqing Pharmaceutical Group. Started Apr 2025; status: completed.
02
Drugs
TQB3702
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on CTR20244964.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20244964.